Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Non Operating Income: 2021-2025

Historic Other Non Operating Income for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$56,994.

  • InMed Pharmaceuticals' Other Non Operating Income fell 395.15% to -$56,994 in Q3 2025 from the same period last year, while for Sep 2025 it was -$104,775, marking a year-over-year decrease of 1892.25%. This contributed to the annual value of -$28,471 for FY2025, which is 54.02% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Other Non Operating Income of -$56,994 as of Q3 2025, which was down 357.46% from $22,137 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Other Non Operating Income peaked at $59,896 during Q4 2023, and registered a low of -$96,791 during Q3 2022.
  • Moreover, its 3-year median value for Other Non Operating Income was -$22,165 (2025), whereas its average is -$10,819.
  • Per our database at Business Quant, InMed Pharmaceuticals' Other Non Operating Income spiked by 573.00% in 2022 and then slumped by 1,662.02% in 2024.
  • InMed Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $3,007 in 2021, then soared by 573.00% to $20,237 in 2022, then spiked by 195.97% to $59,896 in 2023, then slumped by 179.73% to -$47,753 in 2024, then crashed by 395.15% to -$56,994 in 2025.
  • Its Other Non Operating Income stands at -$56,994 for Q3 2025, versus $22,137 for Q2 2025 and -$22,165 for Q1 2025.